Alto Neuroscience Inc (ANRO) Stock Price, Quote & News

Latest News on ANRO

Jun 3, 2025, 6:03 AM EDT - 2 days ago

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

May 29, 2025, 8:03 AM EDT - 7 days ago

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

May 28, 2025, 8:03 AM EDT - 8 days ago

Alto Neuroscience to Participate in Upcoming Investor Conferences

May 14, 2025, 4:10 PM EDT - 22 days ago

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 28, 2025, 8:03 AM EDT - 5 weeks ago

Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach

Apr 22, 2025, 8:03 AM EDT - 6 weeks ago

Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day

Mar 20, 2025, 4:10 PM EDT - 2 months ago

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

Mar 1, 2025, 11:00 AM EST - 3 months ago

The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation

Feb 19, 2025, 8:03 AM EST - 3 months ago

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Feb 12, 2025, 8:03 AM EST - 4 months ago

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

Feb 2, 2025, 11:00 AM EST - 4 months ago

The Schall Law Firm Invites Investors With Losses To Join An Investigation Into Alto Neuroscience, Inc. For Securities Fraud

Jan 27, 2025, 11:15 AM EST - 4 months ago

The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Investigation Into Alto Neuroscience, Inc.

Jan 24, 2025, 1:15 PM EST - 4 months ago

The Schall Law Firm Invites Investors With Losses To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Jan 22, 2025, 11:45 AM EST - 4 months ago

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Jan 3, 2025, 1:30 PM EST - 5 months ago

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Alto Neuroscience Inc For Securities Fraud

Dec 27, 2024, 12:15 PM EST - 5 months ago

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Alto Neuroscience Inc For Securities Fraud

Dec 21, 2024, 12:15 PM EST - 5 months ago

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Alto Neuroscience Inc For Securities Fraud

Dec 17, 2024, 1:45 PM EST - 6 months ago

The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Dec 15, 2024, 1:45 PM EST - 6 months ago

The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Dec 13, 2024, 2:15 PM EST - 6 months ago

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Possible Securities Fraud

Dec 11, 2024, 5:15 PM EST - 6 months ago

The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into Alto Neuroscience, Inc.'s Possible Securities Fraud

Dec 11, 2024, 8:03 AM EST - 6 months ago

Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology

Dec 9, 2024, 5:30 PM EST - 6 months ago

The Schall Law Firm Urges Stockholder Contributions To An Inquiry Into Alto Neuroscience, Inc. For Possible Securities Fraud

Dec 8, 2024, 10:30 AM EST - 6 months ago

Alto Neuroscience Inc Is Being Investigated For Violating Securities Laws And Impacted Investors Are Invited To Reach Out To The Schall Law Firm

Dec 7, 2024, 12:15 PM EST - 6 months ago

The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Fraud

Dec 5, 2024, 1:45 PM EST - 6 months ago

The Schall Law Firm Encourages Stockholder Contributions To An Inquiry Into Alto Neuroscience, Inc.'s Possible Securities Fraud

Dec 3, 2024, 4:45 PM EST - 6 months ago

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc.'s Possible Securities Fraud

Dec 1, 2024, 1:00 PM EST - 6 months ago

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Nov 29, 2024, 12:00 PM EST - 6 months ago

The Schall Law Firm Invites Shareholder Contributions To An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Nov 27, 2024, 11:30 AM EST - 6 months ago

Alto Neuroscience Inc Is Being Investigated For Violating Securities Laws And Affected Investors Are Encouraged To Reach Out To The Schall Law Firm

Nov 26, 2024, 11:30 AM EST - 6 months ago

The Schall Law Firm Invites Stockholder Contributions To An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Nov 25, 2024, 12:15 PM EST - 6 months ago

Alto Neuroscience Inc Is Being Investigated For Violating Securities Laws And Investors With Losses Are Urged To Contact The Schall Law Firm

Nov 24, 2024, 1:45 PM EST - 6 months ago

The Schall Law Firm Requests Stockholders To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud

Nov 23, 2024, 2:30 PM EST - 6 months ago

Market Cap	66.33M
Revenue (ttm)	0.00
Net Income (ttm)	-61.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.14

Volume	247,250
Avg Vol	253,222
Day's Range	N/A - N/A
Shares Out	27.07M
Stochastic %K	13%
Beta	1.93
Analysts	Strong Sell
Price Target	$10.36